rasburicase 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
enzymes 4994 134774-45-1

Description:

MoleculeDescription

Synonyms:

  • rasburicase
  • fasturtec
  • elitek
a recombinant form of enzyme that degrades uric acid to allantoin just downstream of xanthine oxidase; used to treat hyperuricaemia
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
14 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
July 12, 2002 FDA SANOFI SYNTHELABO
Feb. 23, 2001 EMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tumour lysis syndrome 497.41 35.36 107 3020 11045 90614275
Cytokine release syndrome 148.73 35.36 50 3077 27923 90597397
Neutropenia 119.99 35.36 82 3045 224822 90400498
Febrile neutropenia 112.10 35.36 69 3058 158280 90467040
Hypofibrinogenaemia 71.48 35.36 15 3112 1355 90623965
Hyperkalaemia 69.18 35.36 37 3090 64927 90560393
Methaemoglobinaemia 64.95 35.36 17 3110 3998 90621322
Hyperuricaemia 60.62 35.36 18 3109 6701 90618619
Blood phosphorus increased 59.01 35.36 16 3111 4302 90621018
Respiratory failure 53.27 35.36 39 3088 118379 90506941
Febrile bone marrow aplasia 46.19 35.36 16 3111 9722 90615598
Renal failure 45.48 35.36 37 3090 130970 90494350
Cerebral haematoma 45.36 35.36 13 3114 4276 90621044
Necrotising colitis 43.84 35.36 10 3117 1328 90623992
Hyperphosphataemia 42.63 35.36 12 3115 3699 90621621
Toxic skin eruption 42.09 35.36 17 3110 15757 90609563
Thrombocytopenia 39.46 35.36 42 3085 208683 90416637
Subdural hygroma 39.17 35.36 7 3120 271 90625049
Multiple organ dysfunction syndrome 38.86 35.36 26 3101 68310 90557010
Cardiovascular insufficiency 36.72 35.36 9 3118 1626 90623694
Haemolytic anaemia 36.08 35.36 14 3113 11683 90613637

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tumour lysis syndrome 662.46 24.61 211 6442 22020 42592662
Methaemoglobinaemia 344.39 24.61 94 6559 5680 42609002
Lymphoid tissue hypoplasia 233.52 24.61 48 6605 830 42613852
Thymus hypoplasia 228.53 24.61 47 6606 815 42613867
Disseminated aspergillosis 175.43 24.61 43 6610 1687 42612995
Febrile neutropenia 155.87 24.61 167 6486 185536 42429146
Cytokine release syndrome 147.96 24.61 90 6563 44437 42570245
Lymphopenia 134.08 24.61 66 6587 21497 42593185
Haemolytic anaemia 102.80 24.61 46 6607 12081 42602601
Cytomegalovirus viraemia 96.47 24.61 42 6611 10335 42604347
Fungal infection 92.62 24.61 50 6603 19672 42595010
Clostridium difficile colitis 86.42 24.61 49 6604 21203 42593479
Bacterial infection 84.02 24.61 53 6600 27826 42586856
Haemolysis 76.90 24.61 35 6618 9554 42605128
Glucose-6-phosphate dehydrogenase deficiency 73.80 24.61 15 6638 244 42614438
Neutropenia 69.60 24.61 117 6536 199314 42415368
SARS-CoV-2 sepsis 50.89 24.61 11 6642 244 42614438
Enterococcus test positive 50.01 24.61 16 6637 1669 42613013
Multiple organ dysfunction syndrome 49.48 24.61 68 6585 96967 42517715
Acute kidney injury 49.34 24.61 147 6506 367190 42247492
Cutaneous T-cell lymphoma stage I 46.38 24.61 9 6644 114 42614568
Hyperphosphataemia 42.38 24.61 26 6627 12978 42601704
Cellulitis 42.18 24.61 50 6603 61535 42553147
Chronic lymphocytic leukaemia 33.66 24.61 16 6637 4813 42609869
Immune effector cell-associated neurotoxicity syndrome 33.62 24.61 20 6633 9441 42605241
Disseminated intravascular coagulation 33.32 24.61 29 6624 24765 42589917
Hyperkalaemia 33.14 24.61 51 6602 80407 42534275
Escherichia infection 32.65 24.61 21 6632 11375 42603307
Renal ischaemia 30.44 24.61 11 6642 1659 42613023
Febrile bone marrow aplasia 29.76 24.61 19 6634 10162 42604520
Hyperuricaemia 28.57 24.61 18 6635 9406 42605276
Myocardial calcification 28.56 24.61 5 6648 34 42614648
Autoimmune haemolytic anaemia 28.35 24.61 15 6638 5656 42609026
Hyperbilirubinaemia 27.45 24.61 24 6629 20611 42594071
Hypoxia 25.65 24.61 42 6611 69744 42544938

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tumour lysis syndrome 1122.01 24.15 299 9195 30502 110549303
Methaemoglobinaemia 410.17 24.15 105 9389 9063 110570742
Cytokine release syndrome 294.57 24.15 136 9358 70170 110509635
Febrile neutropenia 273.34 24.15 222 9272 316545 110263260
Lymphoid tissue hypoplasia 266.75 24.15 54 9440 1611 110578194
Thymus hypoplasia 260.13 24.15 53 9441 1634 110578171
Disseminated aspergillosis 217.84 24.15 49 9445 2431 110577374
Neutropenia 172.08 24.15 185 9309 374435 110205370
Lymphopenia 169.01 24.15 78 9416 40092 110539713
Haemolytic anaemia 163.12 24.15 63 9431 20857 110558948
Cytomegalovirus viraemia 119.20 24.15 48 9446 17716 110562089
Bacterial infection 112.81 24.15 62 9432 45974 110533831
Fungal infection 101.82 24.15 60 9434 50746 110529059
Clostridium difficile colitis 99.18 24.15 56 9438 43722 110536083
Hyperkalaemia 95.81 24.15 85 9409 135711 110444094
Acute kidney injury 87.87 24.15 178 9316 635252 109944553
Haemolysis 87.11 24.15 37 9457 15602 110564203
Multiple organ dysfunction syndrome 85.87 24.15 84 9410 151626 110428179
Glucose-6-phosphate dehydrogenase deficiency 78.76 24.15 16 9478 485 110579320
Hyperuricaemia 76.39 24.15 33 9461 14498 110565307
Hyperphosphataemia 72.59 24.15 33 9461 16348 110563457
Blood phosphorus increased 69.53 24.15 32 9462 16308 110563497
Sepsis 63.15 24.15 106 9388 327240 110252565
Thrombocytopenia 58.23 24.15 106 9388 348779 110231026
Disseminated intravascular coagulation 58.14 24.15 39 9455 41247 110538558
SARS-CoV-2 sepsis 57.02 24.15 11 9483 254 110579551
Respiratory failure 55.89 24.15 80 9414 215252 110364553
Febrile bone marrow aplasia 55.50 24.15 28 9466 17437 110562368
Blood lactate dehydrogenase increased 51.01 24.15 37 9457 44297 110535508
Enterococcus test positive 50.85 24.15 16 9478 2888 110576917
Immune effector cell-associated neurotoxicity syndrome 50.81 24.15 25 9469 14757 110565048
Cutaneous T-cell lymphoma stage I 49.90 24.15 9 9485 142 110579663
Cellulitis 47.00 24.15 56 9438 125960 110453845
Pseudomonal sepsis 45.77 24.15 20 9474 9026 110570779
Hypoxia 44.15 24.15 55 9439 129460 110450345
Chronic lymphocytic leukaemia 43.06 24.15 17 9477 5951 110573854
Renal failure 41.83 24.15 72 9422 226502 110353303
Blood uric acid increased 39.41 24.15 24 9470 21505 110558300
Hypocalcaemia 38.45 24.15 37 9457 65329 110514476
Pyrexia 37.27 24.15 164 9330 898101 109681704
Encephalopathy 36.97 24.15 40 9454 81015 110498790
Necrotising colitis 36.29 24.15 11 9483 1754 110578051
Anaemia 36.10 24.15 116 9378 546970 110032835
Hypertriglyceridaemia 34.78 24.15 20 9474 16134 110563671
Renal ischaemia 33.32 24.15 11 9483 2312 110577493
Cardiovascular insufficiency 33.29 24.15 12 9482 3276 110576529
Hepatocellular injury 32.33 24.15 30 9464 50612 110529193
Cerebral haematoma 32.24 24.15 16 9478 9616 110570189
Neutropenic sepsis 31.64 24.15 24 9470 30722 110549083
Haemophagocytic lymphohistiocytosis 31.09 24.15 24 9470 31535 110548270
Autoimmune haemolytic anaemia 30.84 24.15 16 9478 10551 110569254
Escherichia infection 29.98 24.15 21 9473 23795 110556010
Enterococcal bacteraemia 29.73 24.15 12 9482 4449 110575356
Inappropriate antidiuretic hormone secretion 29.60 24.15 24 9470 33827 110545978
Pancytopenia 29.14 24.15 59 9435 209554 110370251
Pain 28.68 24.15 24 9470 954931 109624874
Hypofibrinogenaemia 28.61 24.15 10 9484 2497 110577308
Haemophilus bacteraemia 28.04 24.15 6 9488 235 110579570
Chronic lymphocytic leukaemia recurrent 27.99 24.15 8 9486 1041 110578764
Subdural hygroma 27.37 24.15 7 9487 599 110579206
Nervous system disorder 26.71 24.15 22 9472 31699 110548106
Transient aphasia 26.28 24.15 7 9487 702 110579103
Fatigue 26.24 24.15 40 9454 1215918 109363887
Leukopenia 25.77 24.15 46 9448 148745 110431060
Transverse sinus thrombosis 25.63 24.15 7 9487 771 110579034
Respiratory distress 24.67 24.15 30 9464 68844 110510961
Product use in unapproved indication 24.34 24.15 89 9405 447288 110132517

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V03AF07 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Detoxifying agents for antineoplastic treatment
FDA CS M0022307 Urate Oxidase
MeSH PA D006074 Gout Suppressants
MeSH PA D018501 Antirheumatic Agents
FDA EPC N0000175670 Uric Acid-specific Enzyme
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35845 gout suppressant

Related Drugs by ATC class:

V03AF Detoxifying agents for antineoplastic treatment 10 drugs
amifostineargininedexrazoxaneglucarpidaseleucovorinlevofolinic acidlysinemesnapalifermintrilaciclib

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hyperuricemia indication 35885006 DOID:1920




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
08GY9K1EUO UNII
D05704 KEGG_DRUG
4021376 VUID
N0000148794 NUI
4021376 VANDF
C0937932 UMLSCUI
CHEBI:749439 CHEBI
CHEMBL1201594 ChEMBL_ID
DB00049 DRUGBANK_ID
7851 INN_ID
C469709 MESH_SUPPLEMENTAL_RECORD_UI
7467 IUPHAR_LIGAND_ID
283821 RXNORM
16841 MMSL
44374 MMSL
53180 MMSL
d04805 MMSL
009162 NDDF
134670005 SNOMEDCT_US
395858003 SNOMEDCT_US
415249009 SNOMEDCT_US

Pharmaceutical products:

None